Paclitaxel + Carboplatin + Pembrolizumab for Breast Cancer

This trial explores how specific blood and imaging tests can determine if individuals with early-stage triple-negative breast cancer (TNBC) have fully responded to chemotherapy before surgery. The study involves various groups receiving combinations of chemotherapy drugs—Paclitaxel, Carboplatin, and Pembrolizumab (an immunotherapy drug)—to assess their effectiveness. Ideal participants have TNBC and can undergo combined chemotherapy and immunotherapy as part of their treatment. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss your current medications with the study team to get specific guidance.

Research has shown that the combination of paclitaxel, carboplatin, and pembrolizumab is generally well-tolerated by patients. However, some individuals report side effects such as nausea, tiredness, and low blood cell counts, which can reduce energy and weaken the immune system. Studies have also found that while the treatment can be effective, it may cause serious side effects for some people. Pembrolizumab, a component of this combination, has been linked to immune-related side effects, such as inflammation in organs like the lungs or liver. These side effects might not occur in everyone, but they are important to consider. Overall, the treatment shows promise, but potential side effects should be considered when deciding to join a trial.¹²³⁴⁵

Researchers are excited about combining Paclitaxel, Carboplatin, and Pembrolizumab for breast cancer because this trio offers a unique approach compared to standard chemotherapy and hormone therapy options. Pembrolizumab is an immunotherapy drug that helps the immune system detect and attack cancer cells, which is different from traditional treatments that directly target cancer cells. This combination could potentially enhance the effectiveness of chemotherapy by boosting the body's natural defenses, providing a dual attack on the cancer. Additionally, using immunotherapy like Pembrolizumab could lead to longer-lasting responses, giving patients more durable outcomes.

Research has shown that combining the drugs paclitaxel, carboplatin, and pembrolizumab yields promising results for treating triple-negative breast cancer (TNBC). Earlier studies demonstrated that adding pembrolizumab to chemotherapy extended patients' lives. Specifically, about 86.6% of patients with early-stage TNBC survived after receiving this treatment. In this trial, participants will join different cohorts; some will receive paclitaxel, carboplatin, and pembrolizumab alone, while others will receive additional cycles of AC/PB. Pembrolizumab-based treatments have become a common choice for early-stage TNBC due to their effectiveness. This combination is known for effectively fighting tumors and generally manageable side effects, offering hope to patients.¹²³⁶⁷